Edition:
United States

Kyowa Hakko Kirin Co Ltd (4151.T)

4151.T on Tokyo Stock Exchange

2,328JPY
20 Feb 2018
Change (% chg)

-- (--)
Prev Close
¥2,328
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,173,787
52-wk High
¥2,371
52-wk Low
¥1,626

Chart for

About

Kyowa Hakko Kirin Co., Ltd. is mainly engaged in medical product and Biochemical businesses. The Medical Product segment is engaged in the manufacture, sale and sales promotion of ethical drug and reagent for clinical test, the development of candidate substances for new drugs, as well as the research and development of... (more)

Overall

Beta: 0.79
Market Cap(Mil.): ¥1,354,736.00
Shares Outstanding(Mil.): 576.48
Dividend: 15.00
Yield (%): 1.15

Financials

  Industry Sector
P/E (TTM): -- 32.45 17.28
EPS (TTM): -- -- --
ROI: -- 14.04 35.61
ROE: -- 15.50 17.17

BRIEF- Kyowa Hakko Kirin sells 66.6 pct stake in unit Kyowa Medex

* Says it sold 66.6 percent stake in wholly owned unit Kyowa Medex Co., Ltd., to Hitachi Chemical Company, Ltd, on Jan. 4

Jan 04 2018

BRIEF-Ultragenyx And Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion For Treatment Of X-Linked Hypophosphatemia In Children

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE BUROSUMAB RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF X-LINKED HYPOPHOSPHATEMIA IN CHILDREN

Dec 15 2017

BRIEF-Reata Pharmaceuticals- Entered Third Supplement To Exclusive License & Supply Agreement With Kyowa Hakko

* REATA PHARMACEUTICALS-ON DEC 7 CO ENTERED THIRD SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO, KYOWA HAKKO KIRIN CO LTD (KHK)

Dec 07 2017

BRIEF-Ultragenyx And Kyowa Kirin Announce Positive 48-Week Data From Adult Phase 3 Study Of Burosumab In X-Linked Hypophosphatemia

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE POSITIVE 48-WEEK DATA FROM ADULT PHASE 3 STUDY OF BUROSUMAB (KRN23) IN X-LINKED HYPOPHOSPHATEMIA Source text for Eikon: Further company coverage:

Dec 04 2017

BRIEF-Kyowa Hakko Kirin Announces FDA Acceptance For Filing And Priority Review Designation Of Mogamulizumab's Biologics License Application

* KYOWA HAKKO KIRIN ANNOUNCES FDA ACCEPTANCE FOR FILING AND PRIORITY REVIEW DESIGNATION OF MOGAMULIZUMAB'S BIOLOGICS LICENSE APPLICATION Source text for Eikon: Further company coverage:

Nov 28 2017

BRIEF-Ultragenyx and Kyowa Hakko Kirin announce FDA not currently planning to hold advisory committee meeting for Burosumab biologics license application

* Ultragenyx and Kyowa Hakko Kirin announce FDA not currently planning to hold advisory committee meeting for Burosumab biologics license application

Nov 01 2017

BRIEF-Kyowa Hakko Kirin says voluntary adoption of International Financial Reporting Standards (IFRS)

* Says it plans to adopt International Financial Reporting Standards (IFRS) as the new accounting method, to replace the Japanese Generally Accepted Accounting Principles

Oct 26 2017

BRIEF-ULTRAGENYX AND KYOWA HAKKO KIRIN ANNOUNCE FDA ACCEPTANCE OF BUROSUMAB’S BIOLOGICS LICENSE APPLICATION

* ULTRAGENYX AND KYOWA HAKKO KIRIN ANNOUNCE FDA ACCEPTANCE AND PRIORITY REVIEW DESIGNATION OF BUROSUMAB’S BIOLOGICS LICENSE APPLICATION

Oct 10 2017

BRIEF- Kyowa Hakko Kirin to sell part of stake in unit Kyowa Medex

* Says it will sell a part of stake in wholly owned unit Kyowa Medex Co., Ltd., to Hitachi Chemical Company, Ltd.

Sep 29 2017

BRIEF- R&I affirms Kyowa Hakko Kirin's rating at "A+" and announces stable outlook -R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I

Aug 25 2017

Earnings vs. Estimates